Claritin OTC Switch In Pediatric Populations Could Pose Concerns For NDAC
This article was originally published in The Tan Sheet
FDA advisory committee members may be hesitant to favor an Rx-to-OTC switch of Schering-Plough's Claritin franchise for younger pediatric patients
You may also be interested in...
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)
OTC labeling for second-generation antihistamines - if the drugs were to switch - may not differ greatly from warnings on existing nonprescription allergic rhinitis symptom relief drugs.
Perrigo promotes in pricing, planning